SLC5A2 and stage 5 chronic kidney disease: Despite treatments like RAAS inhibitors, blood pressure, and glycemic control, newer drugs such as SGLT-2 inhibitors and GLP-1 receptor agonists, high-risk obese and diabetic populations remain vulnerable to progressing to end-stage renal disease (ESRD).